Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids
- 18 May 2010
- journal article
- Published by Wiley in Clinical Endocrinology
- Vol. 72 (6) , 853-855
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: Effects on orbital lymphocytic infiltratesClinical Immunology, 2009
- Evidence of Intrathyroidal B-Lymphocyte Depletion after rituximab Therapy in a Patient with Graves’ DiseaseThe Journal of Clinical Endocrinology & Metabolism, 2007
- Rituximab Induces Distinct Intraorbital and Intrathyroidal Effects in One Patient Satisfactorily Treated for Graves’ OphthalmopathyClinical Reviews in Allergy & Immunology, 2007
- Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open studyEuropean Journal of Endocrinology, 2007
- Treatment-Resistant Severe, Active Graves' Ophthalmopathy Successfully Treated with B Lymphocyte DepletionThyroid®, 2006
- Rituximab, an Anti-CD20 Monoclonal Antibody: History and Mechanism of ActionAmerican Journal of Transplantation, 2006
- B Cells, Be Gone — B-Cell Depletion in the Treatment of Rheumatoid ArthritisNew England Journal of Medicine, 2004